How do I prescribe a Dexcom G6 continuous glucose monitor for a patient with unstable type 1 diabetes and life‑threatening hypoglycemia who has Medicaid insurance in North Carolina?

Prescribing Dexcom G6 CGM for a Type 1 Diabetes Patient with Medicaid in North Carolina

For your patient with unstable type 1 diabetes and life-threatening hypoglycemia on Medicaid in North Carolina, prescribe the Dexcom G6 CGM with a detailed prescription including diagnosis codes, medical necessity documentation, and direct coordination with a Medicaid-approved durable medical equipment (DME) supplier who can navigate the prior authorization process. 1

Step-by-Step Prescription Process

1. Documentation Requirements

Your prescription must include comprehensive medical necessity documentation:

• Diagnosis codes: Type 1 diabetes (E10.65 for hypoglycemia with coma, or E10.649 for hypoglycemia without coma)
• Clinical justification: Document history of severe hypoglycemia episodes, frequency of events, and life-threatening nature
• Current insulin regimen: Specify multiple daily injections (MDI) or pump therapy
• Blood glucose monitoring frequency: Document current fingerstick frequency (typically 4+ times daily)
• Failed conventional management: Note inadequate control with standard SMBG alone

The 2023 Endocrine Society guidelines strongly recommend CGM over fingerstick monitoring for all type 1 diabetes patients on MDI (strong recommendation, moderate quality evidence) 1, making your clinical justification straightforward.

2. Write the Prescription

Include these specific elements:

• Device: Dexcom G6 CGM system (FDA-approved iCGM device) 2
• Supplies needed:
  • Dexcom G6 receiver or compatible smartphone
  • Sensors (quantity: 3 per month for 10-day wear)
  • Transmitter (quantity: 1 every 3 months)
• Duration: Ongoing/continuous use
• Medical necessity statement: "Patient has type 1 diabetes with recurrent severe hypoglycemia and impaired awareness. CGM is medically necessary to prevent life-threatening hypoglycemic events and reduce morbidity/mortality risk."

3. Navigate Medicaid Coverage

Critical insurance considerations 3:

• North Carolina Medicaid typically covers CGM for type 1 diabetes, but requires prior authorization
• Prior authorization requirements:
  • Diagnosis of type 1 diabetes
  • Insulin use (MDI or pump)
  • Documentation of hypoglycemia risk
  • Prescription from licensed provider
  • Patient education plan

Common pitfall: Insurance and cost barriers are the most frequently cited obstacles to CGM prescription in primary care 3. Address this proactively by working with DME suppliers experienced in Medicaid authorization.

4. Select and Coordinate with DME Supplier

Essential step: Identify a Medicaid-contracted DME supplier who:

• Accepts North Carolina Medicaid
• Has experience with Dexcom G6 authorization
• Provides patient education and technical support
• Can handle the prior authorization paperwork

Practical approach 4: Create a directory of local DME suppliers who accept Medicaid. Many primary care practices have successfully expanded CGM access by establishing relationships with specific DME companies that streamline the authorization process.

5. Patient Education Requirements

The guidelines emphasize that comprehensive patient education is critically important for successful CGM use 1:

• Device training: How to insert sensors, use receiver/smartphone app, respond to alarms
• Data interpretation: Understanding glucose trends, time in range, pattern recognition
• Troubleshooting: Sensor failures, connectivity issues, when to use fingerstick confirmation
• Ongoing SMBG access: Patients must continue to have fingerstick supplies for sensor warm-up periods and when symptoms don't match sensor readings 1

Coordinate with device company representatives for initial training 4, or refer to diabetes education services if available.

6. Follow-Up Plan

• Schedule follow-up within 2-4 weeks of CGM initiation
• Review downloaded CGM data (time in range, hypoglycemia frequency, patterns)
• Adjust insulin regimen based on CGM trends
• Ensure patient is wearing device "as close to daily as possible for maximal benefit" 2
• Address any skin reactions from adhesive 2

Key Clinical Considerations

Why this matters for your patient: The Endocrine Society guidelines specifically identify patients with history of severe hypoglycemia and life-threatening events as high-risk individuals who benefit most from CGM 1. For type 1 diabetes with unstable control and severe hypoglycemia, CGM reduces hypoglycemia burden and improves quality of life while reducing morbidity and mortality risk.

Accuracy considerations: The Dexcom G6 is FDA-approved as a nonadjunctive device (no fingerstick confirmation required for treatment decisions) 2, though recent real-world data shows accuracy improves after the first few days of wear 5. Educate patients that fingerstick confirmation is still recommended when symptoms don't match sensor readings.

Alternative if authorization fails: If Medicaid denies coverage despite appropriate documentation, consider:

• Appealing with additional clinical documentation emphasizing life-threatening nature
• Requesting peer-to-peer review with Medicaid medical director
• Exploring manufacturer patient assistance programs
• Documenting access barriers for future policy advocacy 6